Raloxifene in Women: Medical Indications Explained

Raloxifene is often mentioned in bodybuilding forums alongside other anti-oestrogens, yet its real home is women's health. In the UK it is a prescription medicine for postmenopausal osteoporosis and, under NICE guidance, an option for reducing breast cancer risk in selected women. Our editorial team looks at what the evidence actually supports and where the limits lie.

What raloxifene is

Raloxifene hydrochloride belongs to the selective oestrogen receptor modulators, usually shortened to SERMs. The word "selective" matters: the drug does not simply block oestrogen everywhere. Instead, it behaves like oestrogen in some tissues and like an anti-oestrogen in others, depending on the receptor subtype, the co-regulator proteins present in each cell and the shape the receptor takes once raloxifene binds to it.

In bone, raloxifene acts as an agonist. It slows the activity of osteoclasts, the cells that break down bone, and helps preserve bone mineral density after the menopause, when the natural fall in oestradiol accelerates bone loss. In breast and uterine tissue, by contrast, it acts as an antagonist, which is why it does not stimulate the endometrium in the way tamoxifen can.

The medicine was developed in the 1980s and 1990s and is taken as a 60 mg tablet once daily according to its UK summary of product characteristics. It is a second-generation SERM, structurally related to but distinct from tamoxifen, and it has a relatively short half-life with extensive first-pass metabolism in the liver.

Because raloxifene is designed for women whose ovaries have stopped producing large amounts of oestrogen, it is not licensed for premenopausal women. Its pharmacology only makes sense in the context of a low-oestrogen environment, and this is the first point that separates genuine clinical use from the way it is discussed in sporting circles.

Licensed indication: postmenopausal osteoporosis

The core licensed indication is the treatment and prevention of osteoporosis in postmenopausal women. The pivotal evidence comes from the MORE trial (Multiple Outcomes of Raloxifene Evaluation), published by Ettinger and colleagues in 1999, which followed more than 7,000 women with osteoporosis for three years.

MORE showed a clear reduction in new vertebral fractures in women taking raloxifene compared with placebo. However, the trial did not demonstrate a significant reduction in non-vertebral fractures, including hip fractures. This is a crucial nuance: raloxifene protects the spine but is not the drug of choice when hip fracture risk dominates.

For that reason, UK practice usually places oral bisphosphonates such as alendronic acid first. NICE technology appraisal guidance considers raloxifene as an alternative for women who cannot take or tolerate bisphosphonates, and the decision is often guided by a fracture risk assessment using tools such as FRAX or QFracture together with a DXA scan.

Raloxifene may be particularly attractive to younger postmenopausal women with spinal osteopenia or osteoporosis who also carry an elevated breast cancer risk, because one tablet then addresses two concerns at once. A specialist or GP will weigh this against the thrombotic risk described below.

Breast cancer risk reduction

A secondary analysis of the MORE trial (Cummings et al., 1999) found that women receiving raloxifene developed fewer invasive oestrogen receptor-positive breast cancers. This observation led to dedicated prevention research and eventually to the large STAR trial, which compared raloxifene directly with tamoxifen.

STAR (Vogel et al., 2006) enrolled almost 20,000 postmenopausal women at increased risk of breast cancer. Raloxifene was roughly as effective as tamoxifen in reducing invasive breast cancer during the original analysis, although later follow-up suggested it retained somewhat less of the protective effect. Importantly, raloxifene caused fewer uterine cancers and fewer thromboembolic events than tamoxifen.

In England and Wales, NICE guideline CG164 on familial breast cancer lists raloxifene as an option for postmenopausal women at moderate or high risk who still have a uterus, provided they do not have a history of thromboembolic disease or endometrial cancer. In the UK this is an off-label use, so prescribers explain this to patients before starting.

Raloxifene does not reduce oestrogen receptor-negative cancers and is not a treatment for established breast cancer. It is a preventive tool for a defined group of women, chosen after a structured risk assessment, usually in a family history clinic.

Risks and contraindications

The most important safety issue is venous thromboembolism. Raloxifene increases the risk of deep vein thrombosis and pulmonary embolism, roughly in the same range as oral HRT. For this reason, it is contraindicated in women with a current or past history of venous thromboembolism, including retinal vein thrombosis.

The RUTH trial (Barrett-Connor et al., 2006) examined women with or at high risk of coronary heart disease. Raloxifene did not reduce coronary events, but it was associated with an increased risk of fatal stroke. Women with a history of stroke or significant stroke risk factors therefore need very careful assessment.

Common, usually milder side effects include hot flushes and leg cramps. Because hot flushes can worsen, raloxifene is not a good fit for women still struggling with vasomotor menopausal symptoms. Peripheral oedema and flu-like symptoms are also reported.

• Do not use in women who could still become pregnant.
• Avoid with a history of venous thromboembolism or prolonged immobilisation.
• Use caution with hepatic impairment and severe renal impairment.
• Unexplained uterine bleeding must be investigated rather than attributed to the drug.
• Stop before planned surgery or long periods of immobility, as advised by the prescriber.

Any of these factors can tip the balance toward another bone-protective option. That is why raloxifene is started only after a consultation that reviews medical history, family history and current medicines.

Raloxifene outside women's health

In sport, raloxifene is sometimes discussed by men who use anabolic steroids, usually in relation to gynaecomastia. It is important to be clear: this is not a licensed indication, and the evidence base consists largely of small studies in adolescent boys with pubertal gynaecomastia rather than adult athletes.

All SERMs, including raloxifene, are prohibited at all times under the World Anti-Doping Agency list, in the class of hormone and metabolic modulators. UK Anti-Doping applies that list to tested athletes, and a positive finding can result in a lengthy ban regardless of the reason given.

Using a prescription medicine without medical supervision means nobody is checking for clotting risk, liver function or interactions. The thrombotic risk described in women does not disappear in men, and the combination with other substances that thicken the blood may be particularly unwise.

Raloxifene obtained without a prescription also carries quality risks. Products sold online as research chemicals have no regulatory oversight from the MHRA, and their content can differ from the label. Our editorial position is simple: if breast tissue changes appear, the right step is a GP assessment, not self-treatment.

Editorial conclusions

Raloxifene is a well-studied SERM whose licensed role is the treatment and prevention of osteoporosis in postmenopausal women, with proven protection against vertebral fractures.

It also reduces the risk of invasive oestrogen receptor-positive breast cancer and is recognised by NICE as a risk-reducing option for selected postmenopausal women.

The main trade-off is an increased risk of blood clots and, in women with heart disease, fatal stroke. Careful selection is what makes raloxifene useful rather than harmful.

If this subject interests you, our editorial team also suggests reading about how SERMs differ from aromatase inhibitors, which blood tests matter for bone health, and the role of calcium and vitamin D in preventing osteoporosis.

References

1. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637–645.
2. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281(23):2189–2197.
3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP STAR P-2 trial. JAMA. 2006;295(23):2727–2741.
4. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–137.
5. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164). London: NICE; 2013.
6. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.